1. Scrip
  2. >>New Products

Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond

Three New Drugs Reached US Market In 2022

 
• By Mandy Jackson

Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution. 

Bristol Myers Squibb office building in Brisbane, CA
BMS launched the last three of nine new drugs in 2022 • Source: Shutterstock

Bristol Myers Squibb Company’s plan to battle back against coming losses of exclusivity (LOE) for its three top-selling products throughout this decade is going largely to plan, according to chief commercialization officer Chris Boerner. The fight against generic and biosimilar competitors for Revlimid, Opdivo and Eliquis will be won through strong commercial execution for Opdualag, Camzyos, Sotyktu – all approved in the US in 2022 – and six other recent product launches.

During the past three years, Boerner’s commercial teams have brought nine new drugs to market that BMS expects to generate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.